Document Detail


FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
MedLine Citation:
PMID:  19018870     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Recent studies have indicated that patients who receive stem cell transplantation (SCT) and rituximab demonstrate an increased risk of developing hypogammaglobulinemia. Such hypogammaglobulinemia has been found to be due to delayed recovery of memory B cells with an abnormal cell marker expression and impaired immunoglobulin production in vitro. However, no predictive factors for the levels of immunoglobulin after autologous SCT and rituximab therapy have been reported. The aim of this study is to clarify the relationships between the FCGR3A-158V/F genotype and the levels of serum immunoglobulin after SCT. METHODS: A total of 24 non-Hodgkin's lymphoma (NHL) patients received autologous SCT with an adjuvant rituximab. The FCGR3A-158V/F genotype was determined in these patients. We also included ten NHL patients who received an identical conditioning regimen and autologous SCT but no rituximab as control patients. RESULTS: The levels of IgG were significantly lower in FCGR3A-158F homozygous patients (n = 9) in comparison to those in FCGR3A-158V carriers (n = 15). Moreover, the levels of IgG and IgA of FCGR3A-158F homozygous patients, but not those of FCGR3A-158V carriers, were significantly lower than those of control patients. CONCLUSIONS: The genotype of FCGR3A determines not only the response to rituximab, but also the levels of immunoglobulin after SCT and an adjuvant rituximab.
Authors:
Mitsufumi Nishio; Tomoyuki Endo; Katsuya Fujimoto; Satoshi Yamamoto; Masato Obara; Keisuke Yamaguchi; Yukari Takeda; Hideki Goto; Ikumi Kasahara; Norihiro Sato; Takao Koike
Publication Detail:
Type:  Journal Article     Date:  2008-11-06
Journal Detail:
Title:  European journal of haematology     Volume:  82     ISSN:  1600-0609     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-12     Completed Date:  2009-01-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  143-7     Citation Subset:  IM    
Affiliation:
Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan. m-nishio@med.hokudai.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  therapeutic use*
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Female
Hematopoietic Stem Cell Transplantation*
Humans
Immunoglobulins / blood*
Lymphoma, Non-Hodgkin / blood,  drug therapy,  genetics,  therapy*
Male
Middle Aged
Polymorphism, Genetic*
Prednisone / administration & dosage
Receptors, IgG / genetics*
Vincristine / administration & dosage
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/CHOP protocol; 0/FCGR3A protein, human; 0/Immunoglobulins; 0/Receptors, IgG; 0/rituximab; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patients with acute coronary syndromes have low tissue factor activity and microparticle count, but ...
Next Document:  Mobility and balance in Parkinson's disease: a population-based study.